We write regarding the administration of the Food and Drug Administration’s (FDA’s) Pediatric Rare Disease Priority Review Voucher (PRV) program, particularly the decision by the previous administration to deny a PRV for a one-time administered novel curative gene therapy that treats sickle cell disease.
Sen. Scott urges FDA to reconsider gene therapy decision.
Share & report
More from Tim Scott
Mr. President, reserving the right to object, I think the Senator and I could do this all night long. I would be happy to, frankly. I don't think we will get to the place where we just have a clear statement condemning anti-Semitism. So…
This legislation does not take sides between traditional finance and new technology. Or Republicans and Democrats. It takes the side of everyday Americans.
Mr. President, in the first 48 hours following the October 7 Hamas terror attack on Israel, violent language and threats against the Jewish community and Israel increased by over 488 percent. This hatred is spreading like wildfire on…
Madam President, I rise today to take a moment to reflect on the remarkable life of Senator Jim Inhofe, who passed away and is now spending time with his Lord and Savior in heaven. I rise for a number of reasons: One, because he was such a…
Other voices in this conversation
